rMeV-preS
An experimental COVID-19 viral-vector vaccine.
General information
rMeV-preS is a candidate COVID-19 vaccine based on a measles virus vector. It facilitates SARS-CoV-2 stabilized prefusion Spike protein expression in cells of vaccinated animal models, which leads to high neutralizing antibody titres production, a potent Th1-biased T cell response, and complete protection in a SARS-CoV-2 challenge (Lu et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
Spike protein Animal model In vitro Mixed substance |
Vero CCL81 cells; cotton rats; IFNAR−/−mice; IFNAR−/−-hCD46 mice; golden Syrian hamsters | 9.41 | The vaccine vector facilitated high immunogen expression in target cells. The vaccine elicited potent SARS-CoV-2 Spike-specific and neutralizing antibody responses in rats and hamsters. It also induced a potent Th1-biased T cell response in mice. Antibody response in mice seemed to be high even after a single dose administration. Vaccinated hamsters did not show any weight loss in a viral challenge, the lung SARS-CoV-2 titres at day 4 post infection were below the detection threshold and the titres in nasal turbinated were only slightly above the threshold in 3 out of 5 animals. The animals were protected from lung pathology, which is in line with observed significant alleviation of pro-inflammatory cytokine expression. |
Mar/09/2021 |
